MX2019005999A - Precipitacion de la fraccion i-iv-1 de inmunoglobulinas plasmaticas. - Google Patents

Precipitacion de la fraccion i-iv-1 de inmunoglobulinas plasmaticas.

Info

Publication number
MX2019005999A
MX2019005999A MX2019005999A MX2019005999A MX2019005999A MX 2019005999 A MX2019005999 A MX 2019005999A MX 2019005999 A MX2019005999 A MX 2019005999A MX 2019005999 A MX2019005999 A MX 2019005999A MX 2019005999 A MX2019005999 A MX 2019005999A
Authority
MX
Mexico
Prior art keywords
plasma
provides
immunoglobins
precipitation
fraction
Prior art date
Application number
MX2019005999A
Other languages
English (en)
Inventor
Schwarz Hans-Peter
Teschner Wolfgang
Bruckschwaiger Leopold
Gundinger Thomas
Nuernberger Julia
Original Assignee
Baxalta Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47833446&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2019005999(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Baxalta Inc filed Critical Baxalta Inc
Publication of MX2019005999A publication Critical patent/MX2019005999A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14Blood; Artificial blood
    • A61K35/16Blood plasma; Blood serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591Stabilisation, fragmentation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14Extraction; Separation; Purification
    • C07K1/30Extraction; Separation; Purification by precipitation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065Purification, fragmentation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14Extraction; Separation; Purification
    • C07K1/145Extraction; Separation; Purification by extraction or solubilisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Métodos para elaborar composiciones de proteínas sanguíneas a partir de plasma agrupado. En una modalidad, se provee un esquema de fraccionamiento con alcohol que permite aumentar significativamente el rendimiento de proteínas sanguíneas purificadas a partir de una muestra de plasma de partida. En una modalidad específica se provee un método de fraccionamiento de plasma agrupado que comprende un paso inicial de precipitación con una concentración elevada de alcohol, a pH bajo. También se proveen composiciones farmacéuticas con proteínas sanguíneas terapéuticas.
MX2019005999A 2012-02-23 2014-08-21 Precipitacion de la fraccion i-iv-1 de inmunoglobulinas plasmaticas. MX2019005999A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261602488P 2012-02-23 2012-02-23

Publications (1)

Publication Number Publication Date
MX2019005999A true MX2019005999A (es) 2019-08-21

Family

ID=47833446

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2014010076A MX365236B (es) 2012-02-23 2013-02-25 Precipitacion de la fraccion i-iv-1 de inmunoglobulinas plasmaticas.
MX2019005999A MX2019005999A (es) 2012-02-23 2014-08-21 Precipitacion de la fraccion i-iv-1 de inmunoglobulinas plasmaticas.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2014010076A MX365236B (es) 2012-02-23 2013-02-25 Precipitacion de la fraccion i-iv-1 de inmunoglobulinas plasmaticas.

Country Status (26)

Country Link
US (1) US9782477B2 (es)
EP (2) EP2817334B1 (es)
JP (1) JP6291423B2 (es)
KR (1) KR101930582B1 (es)
CN (1) CN104245730B (es)
AR (1) AR090425A1 (es)
AU (1) AU2013203112B2 (es)
BR (1) BR112014020602B1 (es)
CA (1) CA2864715A1 (es)
CL (1) CL2014002225A1 (es)
CO (1) CO7081143A2 (es)
DK (1) DK2817334T3 (es)
EA (1) EA032478B1 (es)
ES (1) ES2928954T3 (es)
HK (1) HK1205520A1 (es)
HU (1) HUE060195T2 (es)
IL (1) IL234103B (es)
MX (2) MX365236B (es)
MY (1) MY167235A (es)
NZ (1) NZ628529A (es)
PL (1) PL2817334T3 (es)
PT (1) PT2817334T (es)
SG (1) SG11201405149UA (es)
SI (1) SI2817334T1 (es)
TW (1) TWI629283B (es)
WO (1) WO2013126904A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013203043B2 (en) 2013-03-15 2016-10-06 Takeda Pharmaceutical Company Limited Methods to produce a human plasma-derived igg preparation enriched in brain disease-related natural iggs
CN104004091B (zh) * 2014-06-12 2016-08-17 新疆德源生物工程有限公司 一种人免疫球蛋白的制备工艺
CN104004090A (zh) * 2014-06-12 2014-08-27 新疆德源生物工程有限公司 一种人免疫球蛋白的制备方法
GB201413227D0 (en) 2014-07-25 2014-09-10 Bioproducts Lab Ltd Process
ES2887588T3 (es) * 2015-08-13 2021-12-23 Kamada Ltd Composiciones derivadas de pasta de fracción de Cohn y uso de las mismas
CN108163898B (zh) * 2018-01-23 2020-12-04 中国科学院上海高等研究院 一种自调节铁氧体材料及其制备方法和应用
AU2021355325A1 (en) * 2020-04-10 2022-11-03 Plasma Technologies, Llc Compositions and methods for simplified high efficiency isolation of proteins
CN116322920A (zh) * 2020-11-09 2023-06-23 武田药品工业株式会社 使用氧化硅吸附从血浆中纯化fviii
CN112250757A (zh) * 2020-11-13 2021-01-22 广东深蓝生物科技有限公司 一种猪血浆中蛋白质的提取纯化方法
JP2024501025A (ja) * 2020-12-28 2024-01-10 プラズマ テクノロジーズ エルエルシー 免疫グロブリンgのプロセススケールでの単離のためのシステム及び方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE348942B (es) 1970-06-02 1972-09-18 Statens Bakteriologiska Labor
US3998946A (en) 1975-04-23 1976-12-21 The Regents Of The University Of Minnesota Fibrinogen-free plasminogen-plasmin-free plasma and method of preparing and using same
US4136094A (en) 1977-08-31 1979-01-23 The Regents Of The University Of Minnesota Preparation of intravenous human and animal gamma globulins and isolation of albumin
US4499073A (en) 1981-08-24 1985-02-12 Cutter Laboratories, Inc. Intravenously injectable immune serum globulin
JPS5855432A (ja) * 1981-09-29 1983-04-01 Fujirebio Inc 静脈注射用免疫グロブリンの製法
DK166763C (da) 1983-03-16 1993-07-12 Immuno Ag Immunoglobulin-g-holdig fraktion
US5177194A (en) 1990-02-01 1993-01-05 Baxter International, Inc. Process for purifying immune serum globulins
FR2706466B1 (fr) 1993-06-14 1995-08-25 Aetsrn Concentré d'immunoglobulines G à usage thérapeutique et procédé de production dudit concentré.
US6284874B1 (en) 1994-06-17 2001-09-04 Alpha Therapeutic Corporation Process for separating α1-proteinase inhibitor from cohn fraction IV1 and IV4 paste
US5616693A (en) 1996-07-01 1997-04-01 Alpha Therapeutic Corporation Process for seperating alpha-1-proteinase inhibitor from COHN IV1 +1V4 paste
TW491855B (en) 1996-08-07 2002-06-21 Csl Ltd Purification of immunoglobulins
CA2232420A1 (en) 1997-03-19 1998-09-19 The Green Cross Corporation Immunoglobulin preparation and preparation process thereof
GB9705810D0 (en) * 1997-03-20 1997-05-07 Common Services Agency Intravenous immune globulin
US5886154A (en) 1997-06-20 1999-03-23 Lebing; Wytold R. Chromatographic method for high yield purification and viral inactivation of antibodies
US6159471A (en) 1997-10-23 2000-12-12 Yoshitomi Pharmaceutical Industries, Ltd. Room temperature storable immunoglobulin preparation for intravenous injection
SE0001128D0 (sv) 2000-03-30 2000-03-30 Amersham Pharm Biotech Ab A method of producing IgG
FR2824568B1 (fr) 2001-05-11 2004-04-09 Lab Francais Du Fractionnement Procede de preparation de concentres d'immunoglobulines humaines a usage therapeutique
EP1413860A4 (en) * 2001-07-05 2009-02-25 Hamamatsu Photonics Kk SPECTROSCOPIC DEVICE
US6893639B2 (en) * 2001-10-19 2005-05-17 Hemacare Corporation Method for high yield purification of immune globulins from blood plasma and blood plasma intermediates
SI1664123T2 (sl) 2003-09-22 2012-03-30 Kamada Ltd Priprava inhibitorja alfa proteinaze v velikem merilu in njegova uporaba
BRPI0507298A (pt) 2004-01-30 2007-07-03 Suomen Punainen Risti Veripalv processo para a produção de imunoglobulina segura a vìrus
KR101206788B1 (ko) 2004-02-27 2012-11-30 옥타파르마 아게 정제된, 바이러스 안전한 항체 제제를 제공하는 방법
US7807435B2 (en) 2005-08-11 2010-10-05 Baxter International Inc. Method for the purification of alpha-1 proteinase inhibitor (a1PI)
WO2008113589A1 (en) 2007-03-20 2008-09-25 Csl Behring Gmbh Methods for industrial scale production of therapeutic complement factor h preparations from human plasma
EP3708581A3 (en) 2009-05-27 2021-10-20 Takeda Pharmaceutical Company Limited A method to produce a highly concentrated immunoglobulin preparation for subcutaneous use
AT516600B1 (de) * 2009-07-23 2016-07-15 Baxter Int Herstellung von faktor h (fh) und fh-derivaten aus plasma
US8772462B2 (en) 2010-05-26 2014-07-08 Baxter International Inc. Removal of serine proteases by treatment with finely divided silicon dioxide
AU2010202125B1 (en) * 2010-05-26 2010-09-02 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation with improved yield
JP5830096B2 (ja) 2010-07-23 2015-12-09 バクスター、インターナショナル、インコーポレイテッド 血漿由来インターα阻害タンパク質(IaIp)の製造方法

Also Published As

Publication number Publication date
TWI629283B (zh) 2018-07-11
AR090425A1 (es) 2014-11-12
NZ628529A (en) 2016-09-30
MY167235A (en) 2018-08-14
WO2013126904A1 (en) 2013-08-29
EA201491564A1 (ru) 2015-04-30
MX2014010076A (es) 2014-09-22
DK2817334T3 (da) 2022-10-03
EA032478B1 (ru) 2019-06-28
BR112014020602A2 (pt) 2018-09-11
IL234103A0 (en) 2014-09-30
BR112014020602B1 (pt) 2022-12-20
SG11201405149UA (en) 2014-09-26
US9782477B2 (en) 2017-10-10
CA2864715A1 (en) 2013-08-29
ES2928954T3 (es) 2022-11-23
CN104245730A (zh) 2014-12-24
PL2817334T3 (pl) 2022-11-21
AU2013203112A1 (en) 2013-09-12
IL234103B (en) 2019-11-28
EP4119574A1 (en) 2023-01-18
EP2817334A1 (en) 2014-12-31
KR101930582B1 (ko) 2018-12-18
US20130224183A1 (en) 2013-08-29
EP2817334B1 (en) 2022-09-21
HUE060195T2 (hu) 2023-02-28
CL2014002225A1 (es) 2015-01-16
HK1205520A1 (en) 2015-12-18
SI2817334T1 (sl) 2022-11-30
TW201348248A (zh) 2013-12-01
AU2013203112B2 (en) 2016-03-10
CO7081143A2 (es) 2014-10-10
MX365236B (es) 2019-05-28
KR20140135996A (ko) 2014-11-27
JP2015509506A (ja) 2015-03-30
JP6291423B2 (ja) 2018-03-14
CN104245730B (zh) 2017-09-01
PT2817334T (pt) 2022-10-17

Similar Documents

Publication Publication Date Title
MX2019005999A (es) Precipitacion de la fraccion i-iv-1 de inmunoglobulinas plasmaticas.
AU2018236800B2 (en) DNA-PK inhibitors
EA201390156A1 (ru) ПРОИЗВОДСТВО ИНТЕР-АЛЬФА-ИНГИБИТОРНЫХ БЕЛКОВ (IaIp) ИЗ ПЛАЗМЫ
EA202090817A1 (ru) Триспецифические белки и способы их применения
MX2018001706A (es) Sales de un inhibidor de dimetilasa 1 especifica para lisina (lsd1).
EA201792573A1 (ru) Триспецифические связанные белки и способы их применения
EA201491012A1 (ru) Гетероциклические ингибиторы глютаминазы
WO2013060867A3 (en) Production of heterodimeric proteins
BR112015031073A2 (pt) inibidores bicíclicos de bromodomínio
IN2014KN00929A (es)
MY168757A (en) Novel compounds as modulators of protein kinases
WO2013177115A3 (en) Novel purification of human, humanized, or chimeric antibodies using protein a affinity chromatography
EA201591229A1 (ru) Способы очистки матричной рнк
BR112013032434A2 (pt) restauração dentária, método para sua produção e vidro cerâmico
EP3816288A3 (en) Modulation of hepatitis b virus (hbv) expression
EA201591685A1 (ru) Способы и промежуточные соединения для получения лекарственного препарата
EA201391489A1 (ru) Композиции со сниженной вязкостью
MX2015005874A (es) Anticuerpos especificos del factor de crecimiento b derivados de plaquetas y composiciones y usos de estos.
EP2649178B8 (en) Mgmt-based method for obtaining high yield of recombinant protein expression
EA201300127A1 (ru) Комбинированная фармацевтическая композиция и способ лечения головокружения различного генеза, кинетоза и вегетососудистой дистонии
IN2014DN06164A (es)
EA201691293A1 (ru) Гетероарильные производные бутановой кислоты в качестве ингибиторов lta4h
EA201071316A1 (ru) Иммуномодуляция ингибиторами ингибиторов апоптоза
MX2020000288A (es) Cromatografia.
MY182519A (en) Method for producing lipid using acyl-acp thioesterase